The diagnosis of procainamide toxicity involves a combination of clinical assessment, laboratory tests, and electrocardiogram (ECG) findings. Blood levels of procainamide and its active metabolite, N-acetylprocainamide (NAPA), can be measured to confirm toxicity. Additionally, ECG changes such as widened QRS complexes or prolonged QT intervals may indicate toxic effects on the heart.
